Breast Cancer

The future of treating patients with triple-negative breast cancer is bright, but more needs to be done to address mutations early on in the course of the disease.

Overall survival results from the MONALESSA-3 phase III trial showed positive results for patients with advanced breast cancer, but toxicities related to the use of ribociclib still need to be addressed.

Management of axillary lymph nodes in patients with breast cancer has undergone some positive changes, but more research is required to treat this patient population properly.

Experts are looking to use immunotherapy in different ways for patients with early-stage breast cancer.

Partial-breast radiation may be more convenient for patients with breast cancer, and according to recent research, the outcomes aren’t much different than patients who had whole-breast radiation.

Patients with a higher likelihood to develop BRCA 1 or BRCA 2 mutations are slipping through the cracks, making testing for these mutations a vital part of any breast cancer treatment plan.

For patients with breast cancer with a PDL1 expression, a new treatment targeting immune cells could make a major difference.

Atezolizumab, along with T-DM1, showed benefit for a subgroup of patients with breast cancer.

A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor-positive breast cancer.

An expert discusses 2 new surgical treatments for breast cancer-associated lymphedema.

About a third of breast cancer survivors are still living with fatigue and reduced exercise capacity after treatment ends.

Partial-breast radiation may be more convenient for patients with breast cancer, and according to recent research, the outcomes aren’t much different than patients who had whole-breast radiation.

Treating patients with HER2-positive metastatic breast cancer is difficult, and patients can fail multiple lines of direct treatment. But now, the FDA has accepted a supplemental new drug application for a combination treatment to help these patients failing multiple treatments.

Here are the top 5 Oncology Nursing News stories for August 2019.

At the 3rd Annual School of Nursing Oncology, Oncology Nursing News had the chance to sit down with Madelaine Kuiper, MSN, RN, and talk about what nurses need to understand about the evolving landscape of breast cancer treatment.

While the US Preventative Services Task Force expanded their recommendations of who should be tested for BRCA mutations, there are still issues left unaddressed, according to one expert.

The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.

With various FDA approvals in the last year alone, nurses must stay up-to-date on the changing treatment landscape of breast cancer to properly treat these patients.

An expert gives an overview of the different treatment approaches for patients with breast cancer that has metastasized to their brain.

After months of debate, the Food and Drug Administration announced that they will be taking action to protect women from breast implant-associated anaplastic large cell lymphoma.

A new surgical method could help treat lymphedema, according to one expert.

By better understanding the subtypes of breast cancer, clinicians can create more personalized and effective treatment plans for patients with breast cancer.

An expert discusses the cardiac toxicity of ABP 980, a trastuzumab biosimilar, in the breast cancer space.

An expert gives an overview of how CDK4/6 inhibitors changed the treatment landscape for patients with metastatic breast cancer.

One expert discusses findings from the TAILORx study.

There is not a major difference in outcomes between whole-breast and partial-breast radiation for some patients with breast cancer.

With a goal of championing the value of patient navigators, Susan G. Komen Greater New York City and NYU Langone have teamed up to provide patients with improved care in Brooklyn through a new patient navigation project.

The Food and Drug Administration (FDA) approved trastuzumab-anns (Kajinti), a biosimilar of trastuzumab (Herceptin) for the treatment of HER2-overexpressing breast cancer, metastatic gastric or gastroesophageal junction adenocarcinoma.

After being treated for breast cancer, nurse practitioners at MSK help survivors transition back to their primary care physicians.

Breast cancer regimens can cause long-term cardiac toxicity in survivors. One trial is delving into why this is the case.